Veeva Systems: The SaaS Business Currently Unloved by the Market
Description: Veeva Systems is a CRM & cloud computing company specializing in software for the life sciences industry. They offer a range of cloud-based applications tailored to the specific needs of these industries, including products for CRM, managing clinical trials, regulatory compliance, sales, and marketing.
Business Segments:
- Subscription-Based Revenue:
- Veeva Development Cloud: This segment serves R&D teams. It involves Vault, a platform that enables content sharing with third parties while ensuring full compliance with regulations. It includes products for Vault Clinical, such as eTMF (clinical trial master file), CTMS (organize trial data), EDC (captures data), Safety Data (collects and organizes adverse event information), and RIM Submission (enables standardization of information). It also includes products for Clinical Data (electronic data capture), Vault Regulatory (supports regulatory submission workflows), and Vault Safety (pharmacovigilance).
- Veeva Quality Cloud: Enables life science partners to develop and manufacture products more efficiently. This includes Vault QMS (quality management systems), Quality Docs to manage regulated content, as well as lab solutions, which enable quality control to optimize batch release testing, stability study management, and environmental monitoring.
- Veeva Commercial Cloud: Centered around Veeva's CRM offering and supports life sciences company’s sales & marketing activities. Outside of the CRM, it involves content generation, medical products, data management, and Crossix.
- Veeva Data Cloud: Largely resembles IQVIA’s product suite by providing data for customer reference, real-time intelligence, and prescriber and sales data from the US market.
- Professional Services and Support: Assistance with implementations of custom Veeva solutions as well as additional design and configuration.
PBC Identification: Veeva is the first ever public company to transition to a Public Benefit Corporation (PBC). As a PBC, Veeva must prioritize a specific social or environmental public benefit alongside generating profits. Therefore, it is legally obligated to consider the interests of stakeholders like employees and the community alongside shareholder returns. For those who prioritize companies who do things differently and value Warren Buffett’s “Institutional Imperative,” this would definitely check the box. Their public governance stance reinforces their long-term mindset.
Competitive Advantages:
- Brand Power and High Market Share: Veeva enjoys strong brand recognition and customer satisfaction within the life sciences CRM market (>80% share of life sciences CRM seats in the industry)
- Barriers to entry: Building a platform tailored to the complex needs of the life sciences industry requires industry expertise, regulatory compliance knowledge, and understanding of scientific workflows
- Switching Costs: Switching platforms in the life sciences industry can be risky due to problems that could arise in data migration, customized configurations, and user training needs.
- Intangible Assets: Veeva's deep domain expertise in the life sciences industry, strong brand recognition, established customer base, and comprehensive software suite are all valuable intangible assets
Historical Growth: Over the past decade ending in 2025, Veeva grew revenue at around 23% per year. Over the same time frame, Veeva grew free cash flow per share at over 35%, despite share dilution of nearly 1.5% per year.
Returns on Capital: Veeva has averaged ~27% ROIC over the past decade ending in 2025. The company has consistently been able to return above-average returns on capital.
Balance Sheet: The balance sheet is pristine, with zero long-term or short-term debt. They have a net cash position of over $5 Billion (depending on recent share buybacks and acquisition costs).
Cash Conversion: For subscription services, customers pay in advance (monthly, quarterly, or annually). This creates negative working capital since the company receives cash before recognizing revenue. Cash conversion (free cash flow/net income), therefore, is unusually high at 146% averaged over the past decade, although their unusually high SBC distorts their free cash flow upwards.
Pricing Power: Veeva famously did not raise prices for their software products from 2008-2021 or so. In their contracts, they implement annual price increases in line with inflation or 4%, whichever is lower. Rather than a value-extracting service provider, they aim to be a partner for their Pharma customers. This has reinforced consistency and a mutually beneficial relationship.
Risks: No company comes without risks.
- Customer Concentration Risks: In their fiscal years ended 2025, 2024, and 2023, their top 10 customers accounted for 28%, 28%, and 29% of their total revenue, respectfully.
- Operational Dependencies: Veeva has used AWS for data centers since 2017 (renewed 10 year partnership in 2025).
- Technological Disruption: VEEV operates an enterprise software platform. There is high and fierce competition amongst other technology providers for life sciences as well as CRM providers like Salesforce. Customers could, in theory, also spend capital on developing internal products tailored to their own needs.
- Customer Consolidation: Consolidation within the life sciences industry has accelerated in recent years, and this trend could continue. With fewer customers comprising a larger percentage of revenue, negotiating power against these companies dwindle.
Veeva is clearly a Quality Company that is trading down due to narrative-based reasons. On a fundamental basis, the engine keeps on chugging, and there are no signs of slowing down. Their partnership-based model and tendency to keep prices low where possible also makes it less likely that pharma clients will leave for competitors, especially given the long-term nature of existing relationships.
What do you all think about Veeva? Agree or Disagree? Other thoughts?